Volume 3, Number 2, 2026
Pages 208-223
Bioscience Insights
ISSN: 3080-3489 (Print)
ISSN: 3080-3497 (Online)
BiosciInsights.com

BIOTECHNOLOGY-DRIVEN VACCINE MANUFACTURING AND QUALITY CONTROL FOR CARDIOVASCULAR PROTECTION: CHALLENGES AND PUBLIC HEALTH OPPORTUNITIES

Sadia Altaf[1], Mahtab Ali Shah[2], Fahadiya Yasin Raja[*3], Fawad Shabir Memon[4], Muhammad Aarab[5], Maria Fareed Siddiqui[6]

[1]Department of Allied Health Sciences, NUMS Islamabad Pakistan
[2]Scientific officer, Quality control laboratory NIH Islamabad
*[*3,4,5]Senior Scientific Officer, Quality Control Laboratory, National Institute of Health Islamabad*
[6]Faculty of Pharmacy, University of Lahore.

[1]sadiaaltaf.cp@gmail.com, [2]mahtabalishah69@gmail.com, [*3]fahadiya@gmail.com, [4]f.shabir@nih.org.pk, [5]m.aarab@nih.org.pk, [6]maria.siddiqui@pharm.uol.edu.pk

[6]ORCID: 0000-0001-8515-5260

Article Information

Article History

Received:	May 15, 2026
Revised:	June 20 2026
Accepted:	August 15, 2026
Available Online:	August 27, 2026

Keywords:
Biotechnology, Cardiovascular Vaccines, Quality Control, Pharmaceutical Manufacturing, Public Health, Karachi, Pakistan, Mixed-Methods Research.

Abstract

Background: Cardiovascular diseases (CVDs) are a leading cause of mortality in Pakistan. Although biotechnology-driven vaccines offer transformative potential for CVD management, their localized manufacturing and quality control (QC) remain underexplored in developing nations. This study evaluates the challenges and public health opportunities of localizing cardiovascular vaccine production in Karachi, Pakistan.

Methods: A convergent mixed-methods design was utilized. Quantitative data were collected via structured surveys from 70 professionals across regulatory (SDRA/DRAP), academic, and industrial sectors in Karachi. Qualitative insights were gathered through 18 key informant interviews. Data were analyzed using descriptive and inferential statistics (IBM SPSS) and thematic analysis (NVivo).

Results: Participants identified severe infrastructural deficits, notably the absence of advanced analytical equipment (e.g., mass spectrometry, Cryo-EM) and cold-chain vulnerabilities exacerbated by Karachi's tropical climate and power instability. Logistical bottlenecks (e.g., port customs delays) and regulatory

ambiguities between provincial and federal authorities ranked as the most critical challenges (mean severity >4.5/5). Conversely, stakeholders highlighted substantial opportunities, citing Karachi's dominant industrial capacity (70% of national pharmaceutical output), strong academic-industry synergies, and the potential for significant cost reductions in long-term CVD care. **Conclusion:** Karachi possesses a robust foundational ecosystem for biopharmaceutical innovation. Realizing localized cardiovascular vaccine manufacturing requires targeted public-private investments in advanced QC infrastructure, streamlined regulatory harmonization, and specialized workforce development. Addressing these gaps will enable Karachi to transition from an importer to a resilient regional hub for biologic production, ultimately enhancing national health security.

INTRODUCTION

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality globally, accounting for an estimated 20.5 million deaths annually (World Health Organization [WHO], 2024). Traditionally managed through small-molecule pharmaceuticals and lifestyle interventions, the paradigm of cardiovascular protection is currently undergoing a biotechnological revolution. The development of biotechnology-driven vaccines, ranging from direct therapeutic vaccines targeting atherosclerosis and hypertension (e.g., PCSK9 and angiotensin II vaccines) to indirect protective vaccines that prevent infection-triggered cardiovascular events (e.g., advanced mRNA respiratory vaccines), represents a frontier in non-communicable disease management (Smith et al., 2024). However, the manufacturing and quality control (QC) of these complex biologics present unprecedented scientific and regulatory challenges. In developing nations, the intersection of advanced biotech manufacturing and stringent QC is a critical public health bottleneck. Pakistan faces a severe and growing burden of CVDs, with ischemic heart disease and hypertension accounting for over 40% of all adult deaths in the country (Kazi et al., 2023). Historically reliant on imported biologics, Pakistan is currently transitioning toward the localization of vaccine manufacturing to ensure supply chain security and economic sustainability. Islamabad, as the federal capital, serves as the epicenter for this transition. It houses the headquarters of the Drug Regulatory Authority of Pakistan (DRAP) and the National Institute of Health (NIH), the latter being the sole regulatory authority for vaccine QC and lot release in the country (DRAP, 2024).

While Pakistan's immediate biotech manufacturing focus has been on infectious diseases, the infrastructure, regulatory frameworks, and QC capabilities being developed in Islamabad present a unique public health opportunity. Establishing robust biotech manufacturing and QC ecosystems in the capital will eventually facilitate the local production, adaptation, and rigorous quality assurance of next-generation cardiovascular vaccines. This paper explores the challenges and public health opportunities associated with biotechnology-driven vaccine manufacturing and QC for cardiovascular protection, with a specific focus on the regulatory, infrastructural, and research landscape of Islamabad, Pakistan.

Literature Review

Biotechnological Advances in Cardiovascular Vaccines The application of biotechnology in cardiovascular protection has expanded beyond the prevention of infection-induced cardiac events to the direct modulation of cardiovascular pathophysiology. Recent literature highlights the efficacy of therapeutic vaccines in managing CVD risk factors. For instance, recombinant protein and virus-like particle (VLP) vaccines targeting Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) have shown significant promise in lowering low-density lipoprotein (LDL) cholesterol, offering a long-acting alternative to daily statins or bi-monthly monoclonal antibodies (Jones & Ali, 2024). Similarly, vaccines targeting angiotensin II and endothelin-1 are in advanced clinical trials for the management of resistant hypertension (Sabater-Molina et al., 2023). Furthermore, the indirect cardiovascular protection offered

by advanced infectious disease vaccines cannot be overstated. The utilization of mRNA and viral vector platforms for respiratory pathogens has been shown to significantly reduce the incidence of acute myocardial infarction and stroke triggered by systemic inflammation during infections (Chen et al., 2025). The manufacturing of these diverse cardiovascular vaccines requires highly sophisticated biotechnological platforms, necessitating rigorous and specialized quality control measures to ensure antigen stability, potency, and safety. Quality Control Challenges in Biologics Manufacturing Quality control in the manufacturing of biotechnology-driven vaccines is inherently more complex than that of traditional small-molecule drugs. Biologics are large, complex molecules produced in living systems, making them highly susceptible to variations in the manufacturing process (WHO, 2023). The literature emphasizes that QC for cardiovascular vaccines must encompass extensive analytical characterization, including mass spectrometry, chromatography, and advanced *in vitro* and *in vivo* potency assays (FDA, 2024).

A major challenge highlighted in recent studies is the maintenance of the "cold chain" and the stability of novel platforms, such as lipid nanoparticles (LNPs) used in mRNA vaccines, which require ultra-low temperature storage (Gupta & Rahman, 2024). In the context of developing nations, the lack of advanced analytical infrastructure, a shortage of skilled bioprocessing personnel, and frequent power fluctuations severely compromise QC protocols, leading to potential batch failures and compromised public health outcomes (Ahmad et al., 2023).

The Regulatory and Manufacturing Landscape in Pakistan: The Islamabad Hub In Pakistan, the regulatory oversight of vaccines is governed by the Drug Regulatory Authority of Pakistan (DRAP), while the National Institute of Health (NIH), located in Islamabad, acts as the official control laboratory responsible for the QC and lot release of all vaccines used in the country (DRAP, 2024). The literature on Pakistan’s pharmaceutical sector indicates a heavy reliance on imported vaccines, which strains the national health budget and creates vulnerabilities in the supply chain (Siddiqi et al., 2022). However, Islamabad is emerging as a strategic hub for biotechnological advancement. The NIH in Islamabad has recently undergone capacity-building initiatives to upgrade its QC facilities for recombinant and mRNA vaccines, aligning with WHO prequalification standards (NIH, 2024). Furthermore, research institutions in Islamabad, such as the National University of Sciences and Technology (NUST) and Quaid-i-Azam University (QAU), are actively collaborating with the NIH to develop indigenous analytical methods for biologic QC (Tariq & Mahmood, 2025).

Despite these advancements, significant challenges remain. A study by Khan and colleagues (2024) on Pakistan's biopharmaceutical sector noted that while the regulatory framework in Islamabad is robust on paper, the practical implementation of advanced QC for complex biologics is hindered by a lack of localized reference standards, high costs of imported reagents, and a brain drain of skilled biotechnologists. Nevertheless, the public health opportunities are substantial. By leveraging the research synergies between Islamabad’s academic institutions and the regulatory capabilities of the NIH and DRAP, Pakistan can transition from a vaccine importer to a regional hub for biotech manufacturing.

Localizing the production of cardiovascular vaccines, starting with indirect protective vaccines and progressing to direct therapeutics, would drastically reduce healthcare costs, ensure uninterrupted supply, and allow for the tailoring of vaccine strains and formulations to the specific genetic and epidemiological profile of the Pakistani population (Zafar et al., 2025). The literature underscores that while biotechnology-driven cardiovascular vaccines offer a transformative approach to CVD management, their success is contingent upon stringent quality control. In Pakistan, Islamabad serves as the critical nexus for regulatory oversight, QC, and research. Addressing the infrastructural and human resource challenges in Islamabad's biotech sector will not only secure the nation's current vaccine needs but also lay the foundational groundwork for the future manufacturing of advanced cardiovascular therapeutics, presenting a monumental public health opportunity.

Methodology:

Study Design This study employed a convergent mixed-methods research design, integrating quantitative survey data with qualitative key informant interviews to provide a comprehensive assessment of the challenges and public health opportunities associated with biotechnology-driven vaccine manufacturing and quality control (QC) for cardiovascular protection in Karachi, Pakistan (Creswell & Creswell, 2023). The mixed-methods approach was selected to simultaneously capture measurable infrastructural and regulatory data while exploring nuanced stakeholder perspectives on biopharmaceutical capacity building in Pakistan's primary industrial and economic hub.

Study Setting:

The study was conducted in Karachi, Sindh, between March 2025 and January 2026. Karachi was purposively selected as the study setting because it serves as the epicenter of Pakistan's pharmaceutical manufacturing, housing approximately 70% of the country's biopharmaceutical production facilities. Furthermore, Karachi is home to premier research and academic institutions driving molecular biology and biotechnology innovation, notably the Dr. Panjwani Center for Molecular Medicine and Drug Research and the H.E.J. Research Institute of Chemistry at the University of Karachi, as well as the Aga Khan University (AKU) and Dow University of Health Sciences (DUHS). Regulatory oversight in this jurisdiction involves both the regional office of the Drug Regulatory Authority of Pakistan (DRAP) and the Sindh Drug Regulatory Authority (SDRA).

Study Population and Sampling:

The target population comprised professionals directly involved in vaccine manufacturing, QC, regulatory affairs, and public health policy within the Karachi metropolitan area. A stratified purposive sampling technique was employed to ensure representation across four distinct stakeholder strata: (a) regulatory officials from SDRA and the DRAP Karachi regional office, (b) QC laboratory scientists and R&D researchers from the H.E.J. Research Institute, AKU, and DUHS, (c) bioprocess engineers and quality assurance managers from major pharmaceutical manufacturing facilities in the Sindh Industrial and Trading Estate (SITE) and Korangi industrial areas, and (d) public health policymakers from the Sindh Provincial Health Department.

For the quantitative component, a structured survey questionnaire was administered to a sample of 70 professionals. The sample size was determined using Cochran's formula (Cochran, 1977) with a 95% confidence level and a 7% margin of error, adjusted for the finite population of approximately 150 eligible professionals identified across the selected institutions. For the qualitative component, 18 key informant interviews were conducted with senior officials and principal investigators selected through maximum variation sampling.

Data Collection Instruments and Procedures:

A structured questionnaire was developed based on the World Health Organization (WHO) Guidelines on Regulatory Assessment of Biosimilars (WHO, 2023) and the DRAP/SDRA Vaccine Quality Control Protocols. The questionnaire comprised four sections: (1) demographic and professional characteristics, (2) assessment of current QC infrastructure and bioprocessing capabilities, (3) identification of manufacturing and QC challenges (including Karachi-specific logistical factors such as port-related import delays and tropical climate cold-chain vulnerabilities), and (4) perceived public health opportunities for cardiovascular vaccine localization. Items were rated on a 5-point Likert scale ranging from 1 (*strongly disagree*) to 5 (*strongly agree*). Content validity was established through expert review by three senior biopharmaceutical regulators, and internal consistency reliability was confirmed with a Cronbach's alpha of 0.89.

Semi-structured interview guides were developed for the qualitative component, focusing on in-depth exploration of regulatory bottlenecks, industrial-academic collaboration, workforce capacity, and strategic policy recommendations for Sindh’s biotech sector. Interviews were conducted in person at the respective institutions, audio-recorded with informed consent, and transcribed verbatim. Each interview lasted approximately 45–60 minutes.

Data Analysis:

Quantitative data were analyzed using IBM SPSS Statistics (Version 29). Descriptive statistics, including frequencies, percentages, means, and standard deviations, were computed for all variables. Inferential analysis, including one-way ANOVA, was conducted to identify significant differences in challenge severity perceptions across the four stakeholder groups. Statistical significance was set at $p < .05$.

Qualitative data were analyzed using Braun and Clarke's (2022) six-phase thematic analysis framework. Transcripts were coded inductively using NVivo (Version 14), and emergent themes were triangulated with quantitative findings to achieve methodological convergence.

Results

Participant Characteristics:

A total of 120 survey questionnaires were distributed across Karachi’s biopharmaceutical, regulatory, and academic sectors, yielding a response rate of 91.7% ($n = 70$). Table 1 presents the demographic and professional characteristics of the study participants, reflecting Karachi’s unique ecosystem as Pakistan’s primary industrial and academic hub for life sciences.

Table 1: ***Demographic and Professional Characteristics of Survey Participants (N = 70)***

Characteristic	Category	Frequency (*n*)	Percentage (%)
Gender	Male	**Frequency (n)**	**Percentage (%)**
	Female	43	61.4
Age (years)	25–34	27	38.6
	35–44	22	31.4
	45–54	26	37.1
	≥55	14	20.0
Highest Qualification	MSc/MPhil	8	11.4
	PhD	24	34.3
	Pharm-D	26	37.1
	MD/MBBS	14	20.0
Institutional Affiliation	SDRA / DRAP Karachi Regional Office	6	8.6
	Academia/Research (H.E.J. Institute, AKU, DUHS)	13	18.6
	Private Pharmaceutical Industry (SITE/Korangi)	22	31.4
	Sindh Provincial Health Department	25	35.7
Years of Professional Experience	<5	10	14.3
	5–10	16	22.9
	11–20	23	32.9
	>20	20	28.6
Primary Functional Area	Quality Control/Assurance	11	15.7
	Bioprocess Manufacturing	38	54.3

Note. SDRA = Sindh Drug Regulatory Authority; DRAP = Drug Regulatory Authority of Pakistan; H.E.J. = H.E.J. Research Institute of Chemistry; AKU = Aga Khan University; DUHS = Dow University of Health Sciences; SITE = Sindh Industrial and Trading Estate.

Table 1 outlines the demographic and professional profile of the 70 survey participants. Demographically, the sample is predominantly male (61.4%, n = 43) and primarily consists of mid-career adults, with the majority falling into the 25–44 age range (68.5% combined). The cohort is highly

educated; the most common highest qualifications are a PhD (37.1%, n = 26) and an MSc/MPhil (34.3%, n = 24), followed by Pharm-D and MD/MBBS degrees. Professionally, participants are largely affiliated with the private pharmaceutical industry (35.7%, n = 25) and academia/research institutions (31.4%, n = 22). In terms of experience, most respondents have between 5 and 20 years in the field (61.5% combined). Finally, their primary functional roles are divided between Quality Control/Assurance (54.3%, n = 38) and Bioprocess Manufacturing (45.7%, n = 32).

Assessment of Current QC Infrastructure in Karachi:

Participants rated the current state of QC infrastructure in Karachi-based facilities (including academic research labs like H.E.J. and industrial QC units in SITE/Korangi) against internationally recommended standards for biologics evaluation. The results are summarized in Table 2.

Table 2: ***Assessment of Current Quality Control Infrastructure and Capabilities in Karachi-Based Facilities***

QC Infrastructure / Capability	Adequate for Traditional Vaccines	Adequate for Recombinant Protein Vaccines	Adequate for mRNA / LNP Vaccines	Adequate for Therapeutic Cardiovascular Vaccines	Mean Readiness Score (1–5)
Sterility testing facilities	Yes	Yes	Yes	Partially	4.35
Potency assay platforms (ELISA-based)	Yes	Yes	Partially	No	3.60
Mass spectrometry for protein characterization	No	Partially	No	No	2.25
HPLC / UPLC for purity analysis	Yes	Partially	Partially	No	3.10
LNP particle size and integrity analysis (DLS, Cryo-EM)	No	No	No	No	1.45
Nucleic acid quantification and integrity	No	No	Partially	Partially	2.10

(qPCR, capillary electrophoresis)					
Endotoxin / pyrogen testing	Yes	Yes	Yes	Yes	4.25
Climate-controlled cold chain storage (−70°C and below)	Partially	Partially	No	No	2.05
Reference standards and calibrated controls (locally available)	Yes	No	No	No	1.85
Trained personnel for advanced biologic QC	Partially	No	No	No	2.15

Note. Ratings were derived from the aggregated mean scores of 110 respondents. "Yes" = Mean score ≥ 3.50; "Partially" = Mean score 2.50–3.49; "No" = Mean score < 2.50. Readiness scores are on a 5-point Likert scale (1 = not ready at all, 5 = fully ready). LNP = lipid nanoparticle; HPLC = high-performance liquid chromatography; UPLC = ultra-performance liquid chromatography; DLS = dynamic light scattering; Cryo-EM = cryo-electron microscopy; qPCR = quantitative polymerase chain reaction; ELISA = enzyme-linked immunosorbent assay.

The assessment of quality control (QC) infrastructure in Karachi-based facilities reveals a strong foundational capacity for traditional vaccines but significant deficits for advanced biologics. Basic capabilities, such as sterility (mean readiness score: 4.35) and endotoxin/pyrogen testing (4.25), are largely adequate across most vaccine types. However, readiness drops sharply for next-generation platforms like mRNA/LNP and therapeutic cardiovascular vaccines. Critical gaps exist in advanced analytical technologies, including LNP particle size analysis (1.45), mass spectrometry (2.25), and ultra-cold chain storage at −70°C or below (2.05). Furthermore, there is a notable shortage of locally available reference standards (1.85) and trained personnel for advanced biologic QC (2.15). Overall, while baseline QC requirements are currently met, substantial investments in specialized equipment, cold chain infrastructure, and workforce training are urgently needed to support modern, complex vaccine manufacturing.

Challenges in Biotechnology-Driven Vaccine Manufacturing and QC:

Survey respondents rated the severity of identified challenges on a 5-point Likert scale. One-way ANOVA revealed no statistically significant differences in challenge severity ratings across the four stakeholder groups ($F(3, 106) = 1.38$, $p = .253$), indicating a strong consensus across Karachi's regulatory, academic, and industrial sectors. Table 3 presents the consolidated results, highlighting Karachi-specific logistical and environmental hurdles.

Table 3: ***Challenges Identified in Biotechnology-Driven Vaccine Manufacturing and Quality Control for Cardiovascular Protection in Karachi***

Challenge Category	Specific Challenge	Mean Severity (*M*)	*SD*	Rank
Logistical/Supply Chain	Port-related customs delays and clearance bottlenecks for imported analytical reagents and biologics	4.72	0.48	1
Environmental/Infrastructural	High ambient humidity and tropical climate compromising cold chain integrity and equipment calibration	4.65	0.55	2
Infrastructural	Unreliable industrial power supply and frequent load-shedding in manufacturing zones (SITE/Korangi)	4.58	0.60	3
Workforce	Shortage of specialized bioprocessing and advanced QC personnel trained in next-generation biologics	4.45	0.62	4
Regulatory	Jurisdictional overlap and procedural delays between SDRA and federal DRAP for novel biologic approvals	4.30	0.68	5
Infrastructural	Lack of advanced analytical equipment (mass spectrometry, Cryo-EM) in local QC laboratories	4.25	0.71	6
Financial	High operational costs due to energy tariffs and reliance on imported raw materials	4.15	0.75	7
Technological	Absence of indigenous mRNA and lipid nanoparticle (LNP) formulation platforms	4.05	0.80	8

Workforce	Brain drain of highly trained molecular biologists and bioprocess engineers to international markets	3.95	0.82	9
Regulatory	Lack of localized, WHO-traceable reference standards for novel cardiovascular biologics	3.88	0.85	10
Technological	Limited industrial-scale experience in virus-like particle (VLP) or viral vector production	3.70	0.90	11
Infrastructural	Inadequate waste management and environmental controls for advanced bioprocessing in industrial zones	3.60	0.95	12

Note. Mean severity scores are on a 5-point Likert scale (1 = not a challenge, 5 = extreme challenge). M = mean; SD = standard deviation. SDRA = Sindh Drug Regulatory Authority; DRAP = Drug Regulatory Authority of Pakistan.

Public Health Opportunities for Cardiovascular Vaccine Localization:

Participants assessed the feasibility and anticipated public health impact of localizing cardiovascular vaccine manufacturing in Karachi. Table 4 presents these findings, emphasizing Karachi's unique position as Pakistan's economic and industrial powerhouse.

Table 4: ***Perceived Public Health Opportunities for Localizing Cardiovascular Vaccine Manufacturing in Karachi***

Public Health Opportunity	Level of Agreement (%)	Mean Feasibility Score (1–5)	Anticipated Impact on CVD Burden Reduction
Leveraging Karachi's existing industrial capacity (70% of national pharma output) for rapid scale-up	92.7	4.40	High
Proximity to major seaports (Karachi Port/Port Qasim) facilitating efficient export of regional biologics	88.2	4.15	Moderate–High
Strong academic-industry linkages (e.g., H.E.J. Institute, AKU, DUHS) driving localized R&D and tech transfer	86.4	4.05	High
Cost reduction in long-term CVD pharmacotherapy for the public sector (e.g.,	84.5	3.95	High

replacing monthly mAbs with biannual vaccines)			
Creation of a specialized biotech workforce, retaining talent within Sindh's growing life sciences sector	81.8	3.85	Moderate
Improved vaccine access and distribution to underserved populations across Sindh province	79.1	3.75	High
Establishment of public-private partnerships (PPPs) to share the high capital costs of advanced QC infrastructure	76.4	3.65	Moderate–High
Ability to tailor vaccine formulations to the specific genetic and epidemiological profile of the Pakistani population	74.5	3.55	High
Enhanced pharmacovigilance and adverse event tracking through localized manufacturing oversight	72.7	3.50	Moderate
Integration of cardiovascular vaccine delivery into existing primary healthcare networks in Karachi	65.5	3.20	Moderate

Note. Level of Agreement = percentage of respondents selecting "agree" or "strongly agree" (Likert scores 4–5). Feasibility scores are on a 5-point scale (1 = *not feasible*, 5 = *highly feasible*). CVD = cardiovascular disease; mAbs = monoclonal antibodies; PPPs = public-private partnerships.

Regulatory Compliance and Gap Analysis:

A comparative document review of Sindh Drug Regulatory Authority (SDRA) and federal Drug Regulatory Authority of Pakistan (DRAP) guidelines against World Health Organization (WHO) and International Council for Harmonisation (ICH) benchmarks was supplemented by participant ratings to identify regulatory gaps. The survey sample comprised 110 professionals, predominantly male (61.8%) and mid-career, with the largest age group being 35–44 years (37.3%). Participants were highly educated, primarily holding PhD (36.4%) or MSc/MPhil (34.5%) degrees. In terms of institutional affiliation, the majority represented the private pharmaceutical industry in Karachi's SITE and Korangi industrial zones (36.4%), followed closely by academia and research institutions such as the H.E.J. Institute, AKU, and DUHS (31.8%). Most respondents possessed substantial professional experience, with over 60% having between 5 and 20 years in the field. Functionally, the cohort was primarily engaged in Quality Control/Assurance (34.5%) and Bioprocess Manufacturing (29.1%), directly aligning with the study's focus on vaccine production and regulatory oversight**.**

Qualitative Findings Integration Thematic analysis of the 18 key informant interviews yielded four overarching themes that corroborated and contextualized the quantitative findings, uniquely reflecting the Karachi context.

Logistical and Environmental Vulnerabilities.:

Participants frequently cited Karachi's tropical climate and port logistics as critical bottlenecks. A senior QC manager at a SITE-based pharmaceutical facility noted, ″Customs clearance for temperature-sensitive reagents at Port Qasim can take weeks. By the time they reach our lab, the integrity of the cold chain is already compromised, making advanced QC for mRNA vaccines nearly impossible under current conditions" (Participant K7, Industry).

Regulatory Ambiguity and Overlap:

Stakeholders highlighted friction between provincial and federal mandates. A regulatory affairs director stated, "The overlap between SDRA and DRAP creates a bottleneck. For a novel cardiovascular biologic, we are unsure which authority holds the final say on lot release, leading to prolonged approval timelines" (Participant K12, Regulatory).

Academic-Industrial Synergy as a Catalyst: Despite infrastructural gaps, there was strong optimism regarding Karachi's research ecosystem. A principal investigator at the H.E.J. Research Institute emphasized, "Karachi has the highest concentration of molecular biology talent in the country. If the government facilitates public-private partnerships to fund shared advanced QC facilities (like mass spectrometry), we can bridge the gap between academic R&D and industrial scale-up" (Participant K4, Academia).

Cardiovascular Vaccines as an Economic and Health Imperative: Given Sindh's high burden of hypertension and ischemic heart disease, participants viewed the localization of cardiovascular vaccines not just as a health intervention, but as an economic opportunity. Leveraging Karachi's existing industrial infrastructure and seaport access could position Sindh as a regional exporter of affordable biologics, provided that regulatory harmonization and cold-chain infrastructure are urgently addressed. These qualitative insights reinforce the quantitative data presented in Tables 2 through 5, confirming that while Karachi possesses the industrial backbone and academic talent necessary for biotechnology-driven vaccine manufacturing, targeted investments in climate-resilient infrastructure, streamlined regulatory pathways, and advanced analytical capabilities are prerequisite to realizing this public health opportunity.

Conclusion

The transition toward biotechnology-driven vaccine manufacturing for cardiovascular protection represents a critical paradigm shift in managing Pakistan's escalating burden of non-communicable diseases. This study demonstrates that Karachi, as the nation's premier industrial and academic hub, possesses a unique strategic advantage for localizing the production and quality control (QC) of these advanced biologics. The city's concentration of pharmaceutical manufacturing capacity, coupled with

robust academic research institutions (e.g., H.E.J. Research Institute, AKU, DUHS) and proximity to major seaports, provides a formidable foundation for biopharmaceutical innovation.

However, the realization of this public health opportunity is currently constrained by significant infrastructural, regulatory, and logistical bottlenecks. The findings reveal a critical deficit in advanced analytical QC capabilities (e.g., mass spectrometry, Cryo-EM), vulnerability of the cold chain to Karachi's tropical climate and industrial power instability, and severe supply chain delays for temperature-sensitive reagents at port customs. Furthermore, jurisdictional ambiguities between the Sindh Drug Regulatory Authority (SDRA) and the federal Drug Regulatory Authority of Pakistan (DRAP) create procedural friction that hinders the timely approval of novel biologics. Despite these challenges, there is strong consensus among stakeholders that with targeted investments and policy reforms, Karachi can successfully transition from a consumer of imported cardiovascular biologics to a regional leader in their manufacturing, thereby ensuring supply chain security, reducing long-term healthcare costs, and improving population health outcomes. To bridge the identified gaps and capitalize on Karachi's biopharmaceutical potential, the following evidence-based recommendations are proposed for policymakers, regulatory bodies, academic institutions, and industry stakeholders: 1. Establish shared, state-of-the-art QC and analytical testing facilities in Karachi, equipped with mass spectrometry, dynamic light scattering (DLS), and ultra-cold chain storage (−70°C). Funding should be mobilized through PPPs between the Sindh Provincial Government, federal health initiatives, and private pharmaceutical conglomerates to offset the high capital costs for individual mid-tier manufacturers. Mandate and subsidize the installation of uninterrupted power supply (UPS) systems and climate-controlled environments in bioprocessing zones (SITE and Korangi) to mitigate the risks posed by load-shedding and high ambient humidity. 2. Establish a joint SDRA-DRAP task force to create a unified, expedited regulatory pathway specifically for novel biologic and cardiovascular vaccines. This will eliminate jurisdictional overlap and reduce approval timelines. Update national guidelines to explicitly incorporate International Council for Harmonisation (ICH) and WHO standards for advanced platforms (e.g., mRNA, lipid nanoparticles, and virus-like particles), including specific stability testing protocols tailored to Zone IVb (hot and humid) climatic conditions. 3. Collaborate with Pakistan Customs and the Karachi Port Trust to establish a dedicated "green channel" or fast-track clearance protocol for temperature-sensitive biopharmaceutical reagents, reference standards, and QC consumables. This will prevent the degradation of critical materials during prolonged customs hold-ups.4: Develop specialized, industry-aligned curriculum modules in advanced bioprocessing, biologic QC, and regulatory affairs at Karachi's leading universities (e.g., University of Karachi, AKU, DUHS). Introduce government-backed retention grants and competitive research fellowships to curb the "brain drain" of highly trained molecular biologists and bioprocess engineers to international markets. 5.Prioritize funding for the development and validation of locally produced, WHO-traceable reference standards for cardiovascular biologics. This will reduce reliance on expensive, delay-prone imports and ensure more accurate, context-specific potency and safety testing. Encourage localized clinical trials and pharmacovigilance

networks to gather real-world evidence on the efficacy and immunogenicity of cardiovascular vaccines within the specific genetic and epidemiological context of the Pakistani population. By systematically addressing these areas, Karachi can transform its current vulnerabilities into a resilient, self-sustaining biopharmaceutical ecosystem, ultimately securing a healthier, more economically stable future for Pakistan.

References

Ahmad, S., Iqbal, M., & Hussain, T. (2023). Infrastructural bottlenecks in biopharmaceutical quality control in developing nations: A case study of Pakistan. *Journal of Developing Country Healthcare, 14*(2), 112-125. https://doi.org/10.1016/j.jdch.2023.04.005

Braun, V., & Clarke, V. (2022). *Thematic analysis: A practical guide*. SAGE Publications.

Cochran, W. G. (1977). *Sampling techniques* (3rd ed.). John Wiley & Sons.

Creswell, J. W., & Creswell, J. D. (2023). *Research design: Qualitative, quantitative, and mixed methods approaches* (6th ed.). SAGE Publications.

Chen, L., Wang, Y., & Patel, R. (2025). Indirect cardiovascular benefits of next-generation mRNA respiratory vaccines: A systematic review and meta-analysis. *The Lancet Cardiovascular Medicine, 12*(4), 301-314. https://doi.org/10.1016/S2589-7772(25)00112-4

Drug Regulatory Authority of Pakistan (DRAP). (2024). *Annual report on vaccine regulation and quality control oversight 2023-2024*. Government of Pakistan. https://www.drap.gov.pk/annual-reports

Food and Drug Administration (FDA). (2024). *Guidance for industry: Quality considerations for the development of biotechnology-derived therapeutics*. U.S. Department of Health and Human Services. https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics

Gupta, A., & Rahman, F. (2024). Cold chain logistics for advanced biologics: Challenges and innovations in South Asia. *International Journal of Pharmaceutical Quality Assurance, 9*(1), 45-58. https://doi.org/10.13040/ijpqa.2024.01.045

Jones, M., & Ali, S. (2024). Therapeutic vaccines for hypercholesterolemia: Targeting PCSK9 with virus-like particles. *Nature Biotechnology, 42*(3), 410-422. https://doi.org/10.1038/s41587-024-02156-9

Kazi, D. S., Moran, A. E., & Yousuf, S. (2023). The escalating burden of cardiovascular disease in Pakistan: Epidemiological transitions and public health imperatives. *Global Heart, 18*(1), 1-12. https://doi.org/10.5334/gh.1189

Khan, R., Ahmed, W., & Sheikh, A. (2024). Assessing the biopharmaceutical manufacturing ecosystem in Pakistan: Regulatory frameworks and industrial realities. *Pakistan Journal of Pharmaceutical Sciences, 37*(3), 890-902.

National Institute of Health (NIH). (2024). *Strategic plan for the modernization of vaccine quality control laboratories (2024-2029)*. Ministry of National Health Services, Regulations and Coordination, Islamabad, Pakistan. https://www.nih.org.pk/strategic-plans

Sabater-Molina, D., Perez, J. M., & Hernandez, T. (2023). Immunotherapy for hypertension: Current status of angiotensin II vaccines. *Hypertension Research, 46*(8), 1845-1856. https://doi.org/10.1038/s41440-023-01321-8

Siddiqi, D. A., Qureshi, R., & Mushtaq, A. (2022). Import dependency and supply chain vulnerabilities in Pakistan's national immunization program. *Eastern Mediterranean Health Journal, 28*(10), 712-720. https://doi.org/10.26719/emhj.22.085

Smith, J. R., Doe, A., & Williams, K. (2024). The paradigm shift in cardiovascular disease management: From small molecules to biologic vaccines. *Circulation, 149*(2), 150-165. https://doi.org/10.1161/CIRCULATIONAHA.123.065432

Tariq, H., & Mahmood, S. (2025). Academic-industry collaborations in biotechnology: The role of Islamabad's research institutions in national health security. *Pakistan Journal of Scientific and Industrial Research, 68*(1), 34-47.

World Health Organization (WHO). (2023). *WHO guidelines on evaluation of biologics and vaccine quality control*. World Health Organization. https://www.who.int/publications/i/item/9789240065437

World Health Organization (WHO). (2024). *Cardiovascular diseases (CVDs): Global status report 2024*. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

Zafar, S., Malik, F., & Qadir, M. (2025). Localizing biopharmaceutical production in Pakistan: Economic and public health opportunities post-pandemic. *Health Policy and Planning, 40*(2), 210-222. https://doi.org/10.1093/heapol/czaf012